文献速递血栓与止血

凝血因子Xa抑制剂治疗重度肥胖患者心房颤动与静脉血栓栓塞

Treatment of atrial fibrillation and venous thromboembolism with factor Xa inhibitors in severely obese patients.
PubMed 文献 · J Thromb Haemost · 2024-09-05

这项多中心回顾性队列研究纳入1736例体重≥150 kg或BMI≥50 kg/m2的重度肥胖成年患者,比较凝血因子Xa抑制剂与华法林治疗心房颤动和/或静脉血栓栓塞的有效性与安全性。结果显示两组卒中、系统性栓塞或静脉血栓栓塞的比值比无差异(OR 1.005;95%CI 0.6-1.68),大出血比值比亦无差异(OR 0.9;95%CI 0.47-1.7),提示阿哌沙班和利伐沙班可作为华法林的安全有效替代方案。

要点

  • 重度肥胖(BMI≥50 kg/m2和/或体重≥150 kg)患者中,凝血因子Xa抑制剂与华法林的卒中、系统性栓塞或静脉血栓栓塞比值无差异。
  • 大出血风险两组无差异(OR 0.9;95%CI 0.47-1.7)。
  • 数据提示阿哌沙班和利伐沙班是华法林的安全有效替代方案。

核心结论

  • 数据提示阿哌沙班和利伐沙班是华法林的安全有效替代方案,用于BMI≥50 kg/m2和/或体重≥150 kg患者心房颤动和/或静脉血栓栓塞的治疗。

研究设计与样本

  • 多中心回顾性队列研究,纳入1736例患有心房颤动和/或静脉血栓栓塞、接受凝血因子Xa抑制剂或华法林治疗的重度肥胖成年患者。
  • 总体队列平均体重164.4 kg,平均BMI 54.6 kg/m2。
  • 结局评估自研究药物启动后12个月。

主要发现

  • 卒中、系统性栓塞或静脉血栓栓塞的比值比无差异(OR 1.005;95%CI 0.6-1.68)。
  • 大出血的比值比无差异(OR 0.9;95%CI 0.47-1.7)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A paucity of data exists to support the use of factor (F)Xa inhibitors in severely obese patients with a weight of ≥150 kg or body mass index (BMI) of ≥50 kg/m2. OBJECTIVES: The purpose of this study was to evaluate whether FXa inhibitors are as safe and effective as warfarin for the treatment of atrial fibrillation (AF) and/or venous thromboembolism (VTE) in individuals with a BMI of ≥50 kg/m2 and/or weight of ≥150 kg. METHODS: This was a multicenter retrospective cohort study of severely obese adult patients with AF and/or VTE treated with a FXa inhibitor or warfarin. The primary effectiveness outcome was composite odds of stroke, systemic embolism, or VTE; the primary safety outcome was odds of major bleeding. Secondary outcomes included incidence of stroke or systemic embolism, VTE, major bleeding, clinically relevant nonmajor bleeding, all-cause mortality, change in anticoagulation, and total number of hospital encounters. Outcomes were assessed for 12 months following initiation of study drug. RESULTS: A total of 1736 patients were included. The mean weight and BMI of the overall cohort were 164.4 kg and 54.6 kg/m2, respectively. There was no difference in odds of stroke, systemic embolism or VTE (odds ratio, 1.005; 95% CI, 0.6-1.68), or major bleeding (odds ratio, 0.9; 95% CI, 0.47-1.7) between groups. CONCLUSION: These data suggest that apixaban and rivaroxaban are safe and effective alternatives to warfarin for the treatment of AF and/or VTE in individuals with a BMI of ≥50 kg/m2 and/or weight of ≥150 kg.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Dobry P, Edwin SB, Haymart B, et al. Treatment of atrial fibrillation and venous thromboembolism with factor Xa inhibitors in severely obese patients. J Thromb Haemost. 2024. PMID: 39243861. doi:10.1016/j.jtha.2024.08.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。